AP NEWS

Phesi Selected as Finalist for 2018 Scrip Award

October 10, 2018

EAST LYME, Conn.--(BUSINESS WIRE)--Oct 10, 2018--Phesi, a technology-enabled, data-driven provider of premier clinical development services, today announced it is a finalist for a 2018 Scrip Award, one of the pharmaceutical and biotech industries’ most prestigious honors. The company has been selected as one of six finalists in the Best Technological Development in Clinical Trials – Tech Sponsor-focused category, which “recognize[s] the promising and disruptive role that digital health technology now plays in clinical drug development,” according to the Scrip Awards 2018 website.

“We are pleased to receive this important recognition from the Scrip Awards 2018 Committee, as it reflects the uniqueness and value of Phesi’s real-time data collection and predictive analytics capabilities in helping clinical trial sponsors get therapies to patients faster and less expensively,” said Gen Li, PhD, MBA, founder and chief executive officer of Phesi. “To be recognized as an industry leader, especially along with some large and major industry players, is a testament to our pioneering work, which we hope will change the way all companies design and implement clinical trials.”

Powered by over 70,000 data sources, Phesi’s proprietary technology platform comprises a suite of data-driven solutions, from integrated development planning, protocol design and optimization, to operational planning and execution, including site selection.

The platform will be showcased at the 14 th Annual Scrip Awards ceremony, which will take place Wednesday, November 28 at the Hilton Hotel Park Lane in London, UK.

More About Phesi

Founded in 2007 as Pharmaceutical Pipeline Enhancement Strategies, Phesi is a dynamic, data-driven drug development company, providing comprehensive clinical development services for life sciences companies around the world. Phesi’s integrated service offerings cover the entire clinical development process: from development planning and indication assessment to protocol evaluation, site selection, and trial implementation management.

Phesi has the industry’s most comprehensive and dynamic clinical trials database and predictive analytics tools, consisting of more than 213,000 completed clinical trials, 604,000 completed clinical research projects, and over 1.6 million investigator records.

The leadership team at Phesi is driving the future of pharmaceutical R&D, offering unique perspectives on the optimal role of digital technology, the importance of building service organizations around new technology, and an overall understanding of the transformation that needs to happen to improve clinical development.

For more information please visit  www.phesi.com. Follow Phesi on  LinkedIn  and  Twitter.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181010005234/en/

CONTACT: Media:

For Phesi

Reba Auslander, 917-836-9308

reba@raliancecommunications.com

KEYWORD: UNITED KINGDOM UNITED STATES EUROPE NORTH AMERICA CONNECTICUT IRELAND

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL RESEARCH SCIENCE GENERAL HEALTH

SOURCE: Phesi

Copyright Business Wire 2018.

PUB: 10/10/2018 07:45 AM/DISC: 10/10/2018 07:45 AM

http://www.businesswire.com/news/home/20181010005234/en

AP RADIO
Update hourly